Penumbra Inc. (NYSE:PEN) is scheduled to be posting its quarterly earnings results after the market closes on Monday, November 14th.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.04. The firm had revenue of $67.20 million for the quarter, compared to analyst estimates of $63.25 million. Penumbra had a net margin of 0.61% and a return on equity of 0.61%. The business’s quarterly revenue was up 33.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.03 earnings per share. On average, analysts expect Penumbra to post $-0.12 EPS for the current fiscal year and $-0.12 EPS for the next fiscal year.

Earnings History for Penumbra (NYSE:PEN)

Penumbra Inc. (NYSE:PEN) traded up 1.35% during mid-day trading on Friday, hitting $64.00. 281,510 shares of the stock were exchanged. Penumbra Inc. has a 52-week low of $40.23 and a 52-week high of $79.49. The company has a 50 day moving average price of $70.24 and a 200 day moving average price of $64.43. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of 2560.00 and a beta of 0.31.

PEN has been the subject of several analyst reports. Zacks Investment Research cut shares of Penumbra from a “buy” rating to a “hold” rating in a report on Wednesday, July 27th. Canaccord Genuity set a $67.00 price target on shares of Penumbra and gave the stock a “buy” rating in a report on Wednesday, July 20th. Finally, BMO Capital Markets initiated coverage on shares of Penumbra in a report on Monday, October 17th. They set an “outperform” rating and a $86.00 price target for the company.

In other news, EVP Robert D. Evans sold 5,300 shares of the business’s stock in a transaction that occurred on Friday, August 26th. The shares were sold at an average price of $71.03, for a total transaction of $376,459.00. Following the completion of the sale, the executive vice president now owns 2,538 shares in the company, valued at approximately $180,274.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Robert D. Evans sold 3,100 shares of the business’s stock in a transaction that occurred on Friday, September 2nd. The stock was sold at an average price of $70.10, for a total transaction of $217,310.00. Following the sale, the executive vice president now owns 2,538 shares of the company’s stock, valued at approximately $177,913.80. The disclosure for this sale can be found here. Insiders own 22.00% of the company’s stock.

Hedge funds have recently modified their holdings of the company. FMR LLC increased its stake in shares of Penumbra by 6.6% in the second quarter. FMR LLC now owns 4,494,768 shares of the company’s stock valued at $267,439,000 after buying an additional 278,722 shares in the last quarter. Timpani Capital Management LLC bought a new stake in shares of Penumbra during the second quarter valued at $2,337,000. American International Group Inc. increased its stake in shares of Penumbra by 452.2% in the second quarter. American International Group Inc. now owns 14,656 shares of the company’s stock valued at $872,000 after buying an additional 12,002 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Penumbra by 41.7% in the second quarter. Franklin Resources Inc. now owns 207,295 shares of the company’s stock valued at $12,334,000 after buying an additional 60,991 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Penumbra by 29.0% in the second quarter. Alliancebernstein L.P. now owns 674,307 shares of the company’s stock valued at $40,121,000 after buying an additional 151,517 shares in the last quarter. Institutional investors and hedge funds own 51.91% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

5 Day Chart for NYSE:PEN

Receive News & Stock Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related stocks with our FREE daily email newsletter.